Alma Minerva Pérez Rios

  • Citations Per Year
Learn More
BACKGROUND AND AIMS The combination of pegylated interferon alfa/ribavirin will likely remain the treatment of choice for HCV genotype 2/3 patients in financially constrained countries for the foreseeable future. Patients with poor on-treatment response may benefit from treatment extension. This study examined the effect of 48 versus 24 weeks of(More)
OBJECTIVE We evaluated the effectiveness of a raltegravir (RAL)-containing regimen plus an optimized background regimen in HIV-1 highly treatment-experienced patients. DESIGN A retrospective cohort, multicentre study was conducted. METHODS Adult (>16 years old) HIV treatment-experience patients starting therapy with a RAL-containing regimen were(More)
  • 1